SE8101065L - Antitrombinberedning - Google Patents

Antitrombinberedning

Info

Publication number
SE8101065L
SE8101065L SE8101065A SE8101065A SE8101065L SE 8101065 L SE8101065 L SE 8101065L SE 8101065 A SE8101065 A SE 8101065A SE 8101065 A SE8101065 A SE 8101065A SE 8101065 L SE8101065 L SE 8101065L
Authority
SE
Sweden
Prior art keywords
pct
sec
date
antithrombin
salts
Prior art date
Application number
SE8101065A
Other languages
Unknown language ( )
English (en)
Other versions
SE459784B (sv
Inventor
Y Uemura
M Nagatomo
S Funakoshi
T Suyama
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of SE8101065L publication Critical patent/SE8101065L/sv
Publication of SE459784B publication Critical patent/SE459784B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE8101065A 1978-01-07 1981-02-17 Stabiliserad torr antitrombinberedning SE459784B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP53000714A JPS597693B2 (ja) 1978-01-07 1978-01-07 抗トロンビン製剤及びその製法

Publications (2)

Publication Number Publication Date
SE8101065L true SE8101065L (sv) 1981-02-17
SE459784B SE459784B (sv) 1989-08-07

Family

ID=11481420

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8101065A SE459784B (sv) 1978-01-07 1981-02-17 Stabiliserad torr antitrombinberedning

Country Status (10)

Country Link
US (1) US4340589A (sv)
JP (1) JPS597693B2 (sv)
BE (1) BE877439A (sv)
CA (1) CA1126652A (sv)
CH (1) CH645537A5 (sv)
FR (1) FR2460138A1 (sv)
GB (1) GB2064545B (sv)
NL (1) NL181781C (sv)
SE (1) SE459784B (sv)
WO (1) WO1980002798A1 (sv)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
EP0035204B2 (en) * 1980-03-05 1991-05-22 Miles Inc. Pasteurized therapeutically active protein compositions
US4363319A (en) * 1980-06-30 1982-12-14 Applied Medical Devices, Inc. Ready-to-use bandage incorporating a coagulant composition and method of preparing same
DE3170001D1 (en) * 1980-09-30 1985-05-23 Bayer Ag Method for the production of an antithrombin-heparin complex and pharmaceutical compositions containing the complex
DE3038163A1 (de) * 1980-10-09 1982-05-06 Boehringer Mannheim Gmbh, 6800 Mannheim Thrombininhibitor, seine herstellung und verwendung
JPS5967228A (ja) * 1982-10-07 1984-04-16 Green Cross Corp:The 寒冷不溶性グロブリンの凍結乾燥方法
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4656254A (en) * 1985-12-02 1987-04-07 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor and antithrombin III
DE3624453A1 (de) * 1986-07-19 1988-01-28 Behringwerke Ag Verfahren zur herstellung von humanem antithrombin iii (atiii), dafuer geeignete vektoren und wirtszellen, so erhaltenes, biologisch aktives atiii und dieses enthaltende arzneimittel
DE3625090A1 (de) * 1986-07-24 1988-01-28 Behringwerke Ag Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung
US4894444A (en) * 1987-07-16 1990-01-16 Merck & Co., Inc. Recovery and purification of immunogens from immunogen-alum complexes
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
CA1341379C (en) 1988-04-28 2002-07-23 Welfide Corporation Purified antithrombin-iii and methods of producing the same
WO1989011297A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
WO1989011298A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Formulation for antibody reagents
US5252557A (en) * 1988-07-25 1993-10-12 Kiyoshi Kita Administration method of antithrombin
CA1336396C (en) * 1988-07-25 1995-07-25 Kiyoshi Kita Intraocular anticoagulant including antithrombin iii and method of administration
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5591431A (en) * 1990-03-09 1997-01-07 G.D. Searle & Co. Enhancement of clot lysis
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
JP3494667B2 (ja) * 1992-10-02 2004-02-09 アベンティス ファーマ株式会社 アンチトロンビンｉｉｉ製剤
CA2137258A1 (en) * 1993-04-05 1994-10-13 Yoshitomi Pharmaceutical Industries Ltd. Liquid preparation of antithrombin-iii and stabilizing method therefor
EP0653212A4 (en) * 1993-04-05 1997-08-20 Green Cross Corp ANTITHROMBIN III COMPOSITION IN LIQUID FORM AND METHOD FOR STABILIZING IT.
US5397479A (en) * 1993-04-26 1995-03-14 International Remote Imaging Systems, Inc. Composition and method for enrichment of white blood cells from whole human blood
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US5989593A (en) * 1996-11-20 1999-11-23 Yoshitomi Pharmaceutical Industries, Ltd. Method for producing antithrombin-III, method for purifying it, and preparation containing it
DE19856443A1 (de) * 1998-12-08 2000-06-21 Centeon Pharma Gmbh Stabilisiertes Antithrombin III-Präparat
US6518406B1 (en) * 1999-06-23 2003-02-11 Octapharma Ag Method for purification of proteins
SE9902388D0 (sv) * 1999-06-23 1999-06-23 Pharmacia & Upjohn Ab Method for purification of proteins
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20020127698A1 (en) * 2001-01-26 2002-09-12 Ralf Geiben Lynn Serpin drugs for treatment of HIV infection and method of use thereof
US8563693B2 (en) * 2001-01-26 2013-10-22 Acceleration Biopharmaceuticals, Inc. Method of treating human immunodeficiency virus infection in a mammal comprising administering heparin-activated antithrombin III
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7498130B2 (en) 2003-05-13 2009-03-03 Massachusetts General Hospital Method of reducing viral load
US20040229778A1 (en) * 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
ES2221817B1 (es) * 2004-07-26 2005-10-01 Probitas Pharma, S.A. "soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas".
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
PT2496246T (pt) 2009-11-03 2018-07-31 Grifols Therapeutics Llc Composição, método e kit para o inibidor da alfa-1 protease
RU2540480C2 (ru) * 2009-11-24 2015-02-10 Грифольс Терапьютикс Инк. Способы, композиции и наборы для лиофилизации
WO2013151727A1 (en) 2012-04-03 2013-10-10 Smith Medical Asd, Inc. Heparin-bulking agent compositions and methods thereof
CN102973526B (zh) * 2012-12-28 2015-09-09 贵州泰邦生物制品有限公司 人抗凝血酶制剂冷冻干燥过程中的保护剂
CN103041380B (zh) * 2012-12-28 2014-08-06 中国医学科学院输血研究所 人抗凝血酶制剂干热处理过程中的稳定剂
WO2018112780A1 (en) * 2016-12-21 2018-06-28 Chung Chin Sun Novel method for blood plasma protein activity preservation
CN111537326B (zh) * 2020-05-07 2023-05-16 天津德祥生物技术股份有限公司 制备冻干血小板的方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA958339A (en) * 1970-09-19 1974-11-26 Yoshio Yoshimura Stabilization of microorganism cells lytic enzyme
SE392038B (sv) * 1971-09-08 1977-03-14 Kabi Ab Forfarande for isolering av antitrombin ur blod eller blodprodukter
JPS5029005B2 (sv) * 1972-05-08 1975-09-19
JPS532931B2 (sv) * 1973-12-05 1978-02-01
US4087415A (en) * 1976-06-09 1978-05-02 William L. Wilson Antithrombin III
JPS6040859B2 (ja) * 1977-07-27 1985-09-12 喜温 三浦 抗血栓性人工医療材料

Also Published As

Publication number Publication date
CH645537A5 (en) 1984-10-15
JPS597693B2 (ja) 1984-02-20
SE459784B (sv) 1989-08-07
CA1126652A (en) 1982-06-29
US4340589A (en) 1982-07-20
FR2460138A1 (fr) 1981-01-23
FR2460138B1 (sv) 1982-10-08
NL181781B (nl) 1987-06-01
NL7905220A (nl) 1981-01-06
BE877439A (fr) 1979-11-05
GB2064545A (en) 1981-06-17
NL181781C (nl) 1987-11-02
JPS5495715A (en) 1979-07-28
GB2064545B (en) 1983-03-09
WO1980002798A1 (fr) 1980-12-24

Similar Documents

Publication Publication Date Title
DK369284D0 (da) Aprotininhomologe med andre aminosyrer i stilling 15 i stedet for lysin, fremgangsmaade til fremstilling heraf samt deres anvendelse som laegemiddel
DE3853922D1 (de) Aminosäurederivate als Amphotere.
SE7600284L (sv) Terapeutisk insulinberedning.
MX6015E (es) Procedimiento para la preparacion de composiciones de globulina de suero inmune,altamente estabilizada
ES2137162T3 (es) Cefalosporinas y homologos, preparaciones y composiciones farmaceuticas.
FI822414L (fi) Syror av n-substituerade 2-pyrrolidon-4-karboxylsyror som befuktningsmedel
SE7904118L (sv) Sett att framstella en urokinaskomposition
DK0490549T3 (da) Stabilisering af calcitonin-holdige farmaceutiske præparater
DE69232205D1 (de) Haarbehandlungszusammensetzung
FI810559L (fi) Nya 3,4,5-trihydroxipiperidinderivat foerfaranden foer deras framstaellning och deras anvaendning som laekemedel samt i djurnaering
ES2090273T3 (es) Estuche para el dosificado especifico de la angiotensina ii.
ES8304151A1 (es) "procedimiento para eliminar total o parcialmente acido aspartico y acido glutamico de hidrolizados proteicos o mezclas de aminoacidos".
PT90362A (pt) Metodo para o tratamento de doencas muco-epiteliais e da pele em mamiferos que utiliza acidos 4-quinolinocarboxilicos e seus derivados e processo para a preparacao de composicoes farmaceuticas que contem os mesmos compostos
DE3867445D1 (de) Injizierbare loesung des thioctsaeuresalzes mit trometamol und/oder basischen aminosaeuren.
DE3863859D1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
SE7904742L (sv) Stabiliserade mjolkproteinhaltiga kompositioner
DK160316C (da) Analogifremgangsmaade til fremstilling af beta-casomorphinanaloge peptider samt pharmakologisk acceptable syreadditionssalte og metalkomplekser deraf
SE8100005L (sv) Vattenhaltiga kompositioner innehallande stabiliserade enzymer
ATE151768T1 (de) 5-(3-isoxazolyl)pyridin-3-carbonsäure-derivate verwendbar als herbizide
ATE152125T1 (de) Neue synthetische isohirudine mit verbesserter stabilität
IT8020504A0 (it) Isonicotinoil derivati di amminoacidi ad azione erbicida.
KR840002654A (ko) 파모티딘의 주사용 조성물의 제조방법
NO883520D0 (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
PT86944A (pt) Verfahren zur isolierung von basalmembranproteinen aus menschlichen und tierischen geweben
SE7712985L (sv) Fasta medel, vilka i vattenhaltiga system utvecklar antimikrobiell verksamhet

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8101065-4

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8101065-4

Format of ref document f/p: F